A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Carcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 04 Jun 2019 Results published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
- 20 Dec 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 17 Nov 2018 New trial record